13 11 20

Information and support

  • Get informed
  • Get support
  • Cut my risk
  • Get involved
  • Research
  • KCP-330-009 (SADAL)

    Acronym: 

    SADAL

    ACTRN/NCT /ethics: 

    KCP-330-009

    Scientific title: 

    Summary of trial and patient characteristics

    Cancer Type Lymphoma
    Trial Type Treatment
    Phase Phase II Tumour Stream Lymphoma
    Age Range 18 years and older Cancer Stage All stages
    Sex Both Anticipated Start Date
    Molecular Target Anticipated End Date
    Cancer Type Lymphoma
    Trial Type Treatment
    Phase Phase II
    Age Range 18 years and older
    Sex Both
    Molecular Target
    Tumour Stream Lymphoma
    Cancer Stage All stages
    Anticipated Start Date
    Anticipated End Date

    Trial Summary

    A Phase 2b open-label study of selinexor in patients with relapsed/ refractory diffuse large B-cell lymphoma. Selinexor against diffuse aggressive lymphoma.

    Lay Summary

    Sponsor / Cooperative group

    KaryoPharm

    Participating Hospitals

    Hospital Clinical Trial Coordinator Email Phone Principal Investigator Recruitment Status
    Ashford Cancer Centre Research Helen Daykin hdaykin@adelaidecancercentre.com.au 08 8292 2240 Not Yet Recruiting